Sold as Edecrin. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 15, 2026, FDA lists 5 applications for Ethacrynate Sodium (sold as Edecrin), first approved Jan 10, 1967, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Ethacrynate Sodium | Part D | $184K | +1% | 0 |
| Jan 10, 1967 | EdecrinNDA 16093 ยท New active ingredient | Bausch | 35 | Marketed |
| Jul 29, 2015 | Ethacrynate SodiumANDA 205473 | Ph Health | 0 | Marketed |
| Aug 23, 2016 | Ethacrynate SodiumANDA 204634 | Mylan Institutional | 0 | Discontinued |
| Nov 17, 2017 | Ethacrynate SodiumANDA 207758 | Zydus Pharms | 0 | Marketed |
| Jun 9, 2020 | Ethacrynate SodiumANDA 208663 | Sterimax | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Zydus Pharms